Ginsenoside Rh2 inhibits vascular endothelial growth factor‐induced corneal neovascularization

다국어 초록 (Multilingual Abstract)

VEGF‐induced neovascularization plays a pivotal role in corneal neovascularization (CoNV). The current study investigated the potential effect of ginsenoside Rh2 (GRh2) on neovascularization. In HUVECs, pretreatment with GRh2 largely attenuated VEGF‐induced cell proliferation, migration, and vessel‐like tube formation in vitro. At the molecular level, GRh2 disrupted VEGF‐induced VEGF receptor 2(VEGFR2)‐Grb‐2‐associated binder 1 (Gab1) association in HUVECs, causing inactivation of downstream AKT and ERK signaling. Gab1 knockdown (by targeted short hairpin RNA) similarly inhibited HUVEC proliferation and migration. Notably, GRh2 was ineffective against VEGF in Gab1‐silenced HUVECs. In a mouse cornea alkali burn model, GRh2 eyedrops inhibited alkali‐induced neovascularization and inflammatory cell infiltrations in the cornea. Furthermore, alkali‐induced corneal expression of mRNAs/long noncoding RNAs in cornea were largely attenuated by GRh2. Overall, GRh2 inhibits VEGF‐induced an‐giogenic effect via inhibiting VEGFR2‐Gab1 signaling in vitro. It also alleviates angiogenic and inflammatory responses in alkali burn‐treated mouse corneas.—Zhang, X.‐P., Li, K.‐R., Yu, Q., Yao, M.‐D., Ge, H.‐M., Li, X.‐M., Jiang, Q., Yao, J., Cao, C. Ginsenoside Rh2 inhibits vascular endothelial growth factor‐induced corneal neovascularization. FASEB J. 32, 3782–3791 (2018). www.fasebj.org